November 2016November 2016
New Product - Odefsey
Odefsey (emtricitabine (FTC), rilpivirine (RPV), tenofovir alafenamide (TAF)) is a fixed dose combination of antiretroviral drugs. Odefsey is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (12 years and older with body weight at least 35 kg) with plasma HIV-1 RNA ≤ 100,000 copies/mL at the start of therapy. The patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of Odefsey. Coadministration of Odefsey with the following drugs is contraindicated due to the potential for serious and/or life threatening events or loss of virologic response and possible resistance to Odefsey: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin; Antimycobacterials: rifampin, rifapentine; Proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole; Glucocorticoid systemic dexamethasone, except as a single dose treatment and Herbal products: St. John’s wort (Hypericum perforatum). Odefsey is available as tablets containing 200 mg FTC, 25 mg RPV, and 25 mg TAF in packs of 30’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au